{"result": "(\"entity\"<|>GLP-1<|>EVENT<|>GLP-1 refers to glucagon-like peptide-1, a hormone involved in glucose metabolism and appetite regulation.)\n##\n(\"entity\"<|>DM2<|>EVENT<|>DM2 refers to Type 2 Diabetes, a chronic condition that affects the way the body processes blood sugar (glucose).)\n##\n(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a leading organization in the United States that provides guidelines and resources for diabetes care and management.)\n##\n(\"entity\"<|>MANUAL SEEN ENDOCRINOLOGÍA<|>ORGANIZATION<|>The Manual SEEN Endocrinología is a reference guide for endocrinology practices, particularly in relation to diabetes management.)\n##\n(\"entity\"<|>INSULINA BASAL<|>EVENT<|>Insulina basal refers to a type of insulin used to control blood sugar levels in patients with diabetes, typically administered once or twice daily.)\n##\n(\"entity\"<|>INSULINA RÁPIDA<|>EVENT<|>Insulina rápida refers to fast-acting insulin that is used to control blood sugar spikes during meals.)\n##\n(\"entity\"<|>INSULINA GLULISINA<|>EVENT<|>Insulina glulisina is a rapid-acting insulin used to manage blood sugar levels in diabetes patients.)\n##\n(\"entity\"<|>INSULINA REGULAR<|>EVENT<|>Insulina regular is a short-acting insulin used to control blood sugar levels, typically administered before meals.)\n##\n(\"entity\"<|>INSULINA GLARGINA U-300<|>EVENT<|>Insulina glargina U-300 is a long-acting insulin formulation used for blood sugar control in diabetes management.)\n##\n(\"entity\"<|>INSULINA DETEMIR<|>EVENT<|>Insulina detemir is a long-acting insulin used to help manage blood sugar levels in diabetes patients.)\n##\n(\"relationship\"<|>GLP-1<|>DM2<|>GLP-1 plays a significant role in the management of Type 2 Diabetes by regulating insulin secretion and appetite<|>8)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>MANUAL SEEN ENDOCRINOLOGÍA<|>The American Diabetes Association provides guidelines that are referenced in the Manual SEEN Endocrinología for diabetes management<|>7)\n##\n(\"relationship\"<|>INSULINA BASAL<|>INSULINA RÁPIDA<|>Insulina basal and insulina rápida are both types of insulin used in the treatment of diabetes, often in combination<|>6)\n##\n(\"relationship\"<|>INSULINA GLULISINA<|>INSULINA REGULAR<|>Both insulina glulisina and insulina regular are used to manage blood sugar levels in diabetes, but they differ in their onset and duration of action<|>5)\n##\n(\"relationship\"<|>INSULINA GLARGINA U-300<|>INSULINA DETEMIR<|>Insulina glargina U-300 and insulina detemir are both long-acting insulins used for blood sugar control in diabetes management<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: istas del receptor de GLP-1 (arGLP-1), señale cuál de las siguientes afirmaciones no es correcta:\n\nA. El principal mecanismo de acción de los arGLP-1 consiste en la inhibición directa de las neuronas de la proopiomelanocortina en el hipotálamo.\nB. Los efectos de GLP-1 sobre el apetito se encuentran mediados en parte por efectos directos sobre la saciedad a nivel del sistema nervioso central.\nC. El núcleo del tracto solitario incluye grupos de neuronas con receptores para GLP-1 que interactúan con las áreas hipotalámicas que regulan la ingesta.\nD. Los efectos de GLP-1 sobre el apetito se encuentran mediados en parte por el retraso del vaciamiento gástrico.\n\nCOMENTARIO\n\nLas terapias basadas en el péptido 1 similar al glucagón (GLP-1) (los agonistas del receptor de GLP-1) afectan al control de la glucosa a través de varios mecanismos, incluido el aumento de la secreción de insulina dependiente de la glucosa, ralentización del vaciado gástrico y reducción del glucagón posprandial y la ingesta de alimentos.\n\nEl efecto de saciedad del GLP-1 puede involucrar tanto los reflejos enteroentéricos dentro de las comidas como los mecanismos de señalización central a través de las comidas, que median los cambios en el apetito y promueven la saciedad.\n\nReferencias:\n- Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n\n### 65. Un paciente con DM2 de 10 años de evolución está en tratamiento con insulina basal y no controla la glucemia. ¿Qué opción de intensificación del tratamiento no está incluida en las guías de la ADA actuales?\n\nA. Insulina basal + insulina rápida en la principal comida.\nB. Una mezcla de insulina antes del desayuno y otra antes de la cena.\nC. Insulina basal más un análogo de GLP-1.\nD. Todas las opciones están incluidas.\n\nCOMENTARIO\n\nSe debe utilizar un enfoque centrado en el paciente para guiar la elección de los agentes farmacológicos. Las consideraciones incluyen comorbilidades (enfermedad cardiovascular, insuficiencia cardíaca, enfermedad renal), riesgo de hipoglucemia, impacto en el peso, coste, riesgo de efectos secundarios y preferencias del paciente.\n\nAntes de iniciar una pauta avanzada que incluya insulina rápida, podría intensificarse la pauta de tratamiento con opciones no insulínicas, si no estaban prescritas previamente\n---\nDIABETES 2\n\nni concurriera intolerancia y/o contraindicación, priorizando las terapias combinadas, con bajo riesgo de hipoglucemia, que favorezcan el control ponderal u otros factores de riesgo cardiovascular. Si aun con estas medidas terapéuticas el sujeto presentara control glucémico inadecuado, se valoraría añadir insulina rápida o cambiar la pauta previa a mezclas bifásicas, en función de las características del paciente (evidencia E).\n\nReferencias:\n• American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-102.\n\n66 Señale el perfil erróneo entre los siguientes perfiles farmacocinéticos de distintos preparados de insulina:\n\nA. Insulina glulisina. Inicio: 0,25 h. Pico: 1 h. Duración: 3-4 h.\nB. Insulina regular. Inicio: 1-3 h. Pico: 6-8 h. Duración: 12-16 h.\nC. Insulina glargina U-300. Inicio: 1 h. Pico: 12-16 h. Duración: 32-34 h.\nD. Insulina detemir. Inicio: 1 h. Pico: 3-9 h. Duración: 6-24 h.\n\n67 En relación con la farmacocinética de las insulinas, señale la afirmación que no es correcta:\n\nA. La absorción más rápida y la duración de acción más corta de los análogos rápidos de insulina se basa en su mayor afinidad por el receptor de insulina y por las proteasas que la degradan.\nB. La insulina no puede atravesar el endotelio para acceder a la circulación sanguínea mientras no está en forma de dímero o de monómero.\nC. En términos de perfil farmacocinético, la insulina lispro, la insulina aspart y la insulina glulisina son similares.\nD. La insulina regular es una solución transparente de cristales de insulina-zinc.\n\nCOMENTARIO\n\nLos análogos de ins\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}